Results 191 to 200 of about 9,412 (255)

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations.

Digestive and Liver Disease
Medical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action.
F. D'amico, F. Lusetti, L. Peyrin-Biroulet, S. Danese   +3 more
semanticscholar   +3 more sources

The Association of Mesalamine With Kidney Disease.

Advances in Chronic Kidney Disease, 2020
The package inserts for products containing 5-aminosalicylic acid, or mesalamine, include the following language regarding the risk of adverse kidney effects: "renal impairment, including minimal change nephropathy, acute and chronic interstitial ...
A. Adiga, D. Goldfarb
semanticscholar   +4 more sources

RETRACTED ARTICLE: Ir-decorated gallium nitride nanotubes as a chemical sensor for recognition of mesalamine drug: a DFT study

Molecular Simulation, 2022
We, the Editor and Publisher of the journal Molecular Simulation, have retracted the following article: Dmitry Olegovich Bokov, Abduladheem Turki Jalil, Forat H. Alsultany, Mustafa Z. Mahmoud, Wanich Suksatan, Supat Chupradit, Maytham T. Qasim & Parvaneh
Dmitry Olegovich Bokov, A. Jalil, F. H. Alsultany, M. Mahmoud, Wanich Suksatan, S. Chupradit, M. T. Qasim, P. Delir Kheirollahi Nezhad   +7 more
semanticscholar   +1 more source

Mesalamine

Hospital Pharmacy, 2007
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Terri Levien, Dennis J. Cada, Danial E. Baker   +2 more
openaire   +2 more sources

Mesalamine-Associated Thrombocytopenia

American Journal of Gastroenterology, 1999
We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine. In contrast to its parent drug, sulfasalazine, which has often been reported to cause serious blood disorders, particularly agranulocytosis, mesalamine has rately been implicated as a cause of
Pierre Michetti, Steven N Fine, Mark A. Peppercorn, Richard J. Farrell   +3 more
openaire   +3 more sources

Mesalamine in Ulcerative Colitis

DICP, 1991
Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is 5-aminosalicylic acid (5-ASA); the only 5-ASA enema preparation currently available in the U.S.
J M Fitzgerald, T D Marsh
openaire   +3 more sources